NXGL

NexGel

NXGL

Attention (50-day avg)0%

Attention rank (50-day avg)#2,625

Bullish sentiment (50-day avg)48%

Price to earnings ratio-0.46

Market capitalization1.7M

Earnings per share-0.74

Dividend yield (TTM)—

Revenue (annual)11.4M

Net income (annual)-2.9M

Social

What share of all stock conversation is about NXGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 24

$NXGL has been downgraded to Hold by Maxim Group, while Raymond James has maintained a Market Perform rating.
The stock has experienced heavy distribution, with a pre-market drop of -9.8% on 19.7M shares, and has been subject to thin-air printing and fade risk on the open.
NEXGEL, Inc. has a clean micro-cap float on Nasdaq, with major catalysts ahead, including a strategic alternatives update, the SilverSeal hospital launch, and the Regenerative eye & aesthetics platform rollout.

Generated by AI

Sentiment

Of the messages about NXGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +54.84	75.91% -17.66
Bearish	—	0%	0% -54.84	24.09% +17.66

Bullish· Jun 21

$NXGL warrants are experiencing high activity, with prices reaching $0.64.
A prominent medical equipment supplier is impressed with NexGel's technology and sees it as a potential acquisition target.
$NXGL is expected to continue its upward trend, with a potential target price of $5.00 and a long-term goal of $8.00.

Bearish· Jan 12

The short program on NXGL was likely too aggressive, leading to a potential bounce if bought at the right price.
The company's news about selling a bandaid on Amazon may have been overhyped, leading to a decline in the stock.
The stock's price has been significantly impacted by short sellers, with some traders experiencing losses and others holding support at $3.

Generated by AI

Topics

Of the messages about NXGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	83.9%
Analysts	—	0%	0%	5.62%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2.25%
Macro	—	0%	0%	3%
Technical Analysis	—	0%	0%	5.24%

Dec 7

NEXGEL, Inc. (NXGL) has announced a share repurchase program, with authorization to purchase up to $500,000 of its common shares.
The program aims to buy back up to 7.5% of the company's outstanding shares at current valuation.
The share repurchase program is part of the company's efforts to return value to shareholders, with two FDA approvals expected in the first quarter of 2023.

Generated by AI

Community

Of the messages about NXGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	14.29%	3.45%	48.72%
Newcomers	100%	85.71%	96.55%	51.28%

Dec 7

$NXGL is up 3.8% in the last 5 minutes, a notable move in the market.
NEXGEL, Inc. has announced a share repurchase program with up to $500,000 authorization to buy back the company's common shares.
The newcomer is excited about the potential of $NXGL, calling it a "Great play" and encouraging others to trade it.

Generated by AI

News

NEXGEL Strategic Reorganization (NASDAQ:NXGL)

4d agoSeeking Alpha

NexGel Shareholders Approve Stock Expansion and Split

Detailed price information for Nexgel Inc (NXGL-Q) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

NexGel shareholders approve share increase and reverse stock split proposals

6d agoInvesting.com

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was...

1mo agoBarchart.com

Deal Dispatch: MunichRe Buys At-Bay, Mavis Tire Closes Pep Boys Purchase, Werewolf Merges With Ambros

1mo agoBenzinga

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

LANGHORNE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: “NXGL”) today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation of a Special Committee for Strategic Review and Value Creation. Leadership Transition Effective August 2

1mo agoYahoo Finance

Also Discussed

Investors talking about NXGL also mention

#	Name	Attention
1	Crexendo Inc.CXDO	0%0
2	Dermata Therapeutics, Inc.DRMA	0%new
3	Iridex Corp.IRIX	0%0
4	Immix Biopharma, Inc.IMMX	0.03%+0.03
5	Celularity Inc. Class A Common StockCELU	0%0
6	Elutia Inc. Class A Common StockELUT	0%new
7	HeartCore Enterprises, Inc.HTCR	0%0
8	Wheeler Real Estate Investment Trust, Inc. 8.75% Preferred StockWHLRD	0%0
9	ICZOOM Group Inc. Class A Ordinary SharesIZM	0%0
10	Viemed Healthcare, Inc.VMD	0%0

NexGel Inc.

Healthcare
Medical Instruments & Supplies

NexGel Inc. is a healthcare and consumer products company that develops and manufactures high-water-content hydrogels and gel-based formulations for wound care, medical diagnostics, transdermal drug delivery, cosmetics, and over-the-counter remedies. The company’s platform focuses on ultra-gentle, skin-friendly materials designed for applications that require comfortable wear, controlled delivery, and broad formulation flexibility. NexGel serves both healthcare and consumer markets through products used in blister care, pain relief, beauty, and cosmetic applications, while also supporting contract manufacturing relationships with other consumer health companies. Its business is organized around hydrogel manufacturing and converting and packaging operations, reflecting a mix of proprietary material science and outsourced product support services. Based in Langhorne, Pennsylvania, NexGel plays a niche role in the specialty materials segment of the healthcare market.

Website

Location

2150 Cabot Boulevard West

Langhorne, PA, 19047

United States

Social

What share of all stock conversation is about NXGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 24

$NXGL has been downgraded to Hold by Maxim Group, while Raymond James has maintained a Market Perform rating.
The stock has experienced heavy distribution, with a pre-market drop of -9.8% on 19.7M shares, and has been subject to thin-air printing and fade risk on the open.
NEXGEL, Inc. has a clean micro-cap float on Nasdaq, with major catalysts ahead, including a strategic alternatives update, the SilverSeal hospital launch, and the Regenerative eye & aesthetics platform rollout.

Generated by AI

Sentiment

Of the messages about NXGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +54.84	75.91% -17.66
Bearish	—	0%	0% -54.84	24.09% +17.66

Bullish· Jun 21

$NXGL warrants are experiencing high activity, with prices reaching $0.64.
A prominent medical equipment supplier is impressed with NexGel's technology and sees it as a potential acquisition target.
$NXGL is expected to continue its upward trend, with a potential target price of $5.00 and a long-term goal of $8.00.

Bearish· Jan 12

The short program on NXGL was likely too aggressive, leading to a potential bounce if bought at the right price.
The company's news about selling a bandaid on Amazon may have been overhyped, leading to a decline in the stock.
The stock's price has been significantly impacted by short sellers, with some traders experiencing losses and others holding support at $3.

Generated by AI

Topics

Of the messages about NXGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	83.9%
Analysts	—	0%	0%	5.62%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2.25%
Macro	—	0%	0%	3%
Technical Analysis	—	0%	0%	5.24%

Dec 7

NEXGEL, Inc. (NXGL) has announced a share repurchase program, with authorization to purchase up to $500,000 of its common shares.
The program aims to buy back up to 7.5% of the company's outstanding shares at current valuation.
The share repurchase program is part of the company's efforts to return value to shareholders, with two FDA approvals expected in the first quarter of 2023.

Generated by AI

Community

Of the messages about NXGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	14.29%	3.45%	48.72%
Newcomers	100%	85.71%	96.55%	51.28%

Dec 7

$NXGL is up 3.8% in the last 5 minutes, a notable move in the market.
NEXGEL, Inc. has announced a share repurchase program with up to $500,000 authorization to buy back the company's common shares.
The newcomer is excited about the potential of $NXGL, calling it a "Great play" and encouraging others to trade it.

Generated by AI

NexGel

Social

Aug 24

Bullish· Jun 21

Bearish· Jan 12

Dec 7

Dec 7

NEXGEL Strategic Reorganization (NASDAQ:NXGL)

NexGel Shareholders Approve Stock Expansion and Split

NexGel shareholders approve share increase and reverse stock split proposals

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

Deal Dispatch: MunichRe Buys At-Bay, Mavis Tire Closes Pep Boys Purchase, Werewolf Merges With Ambros

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

Also Discussed

NexGel Inc.

Company Information

Location

NEXGEL Strategic Reorganization (NASDAQ:NXGL)

NexGel Shareholders Approve Stock Expansion and Split

NexGel shareholders approve share increase and reverse stock split proposals

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

Deal Dispatch: MunichRe Buys At-Bay, Mavis Tire Closes Pep Boys Purchase, Werewolf Merges With Ambros

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

Also Discussed

Social

Aug 24

Bullish· Jun 21

Bearish· Jan 12

Dec 7

Dec 7